Last updated: February 13, 2026
What Is the Market Position of NDC 52427-0441?
NDC 52427-0441 is identified as Vasopressin Injection, USP, a synthetic form of the hormone vasopressin used primarily for vasodilatory shock, cardiac arrest, and certain diabetes insipidus cases. It is a generic formulation, marketed by multiple manufacturers and approved by the FDA since its original approval in the late 20th century.
Its market performance is influenced by several factors:
- Widely used in hospitals for critical conditions
- Availability of alternative vasopressors such as norepinephrine and epinephrine
- Competitive generic landscape
How Large Is the Current Market for Vasopressin Injections?
Market Size and Trends
Based on recent data (Q2 2022–Q2 2023):
| Metric |
Value |
Notes |
| Global market value |
Approx. $200 million |
Primarily driven by U.S. hospital sales |
| U.S. market share |
70% of sales |
Largest market, hospital procurement dominates |
| Annual growth rate |
2-3% |
Slow but steady, influenced by hospital formulary decisions |
Key Market Drivers
- Increase in sepsis and shock cases
- Rising adoption of vasopressors in emergency care
- Patent expiries of similar drugs expanding generic options
- Hospitals prioritizing cost-effective treatments
Competition Profile
Main competitors include:
- Branded vasopressin products (e.g., AVP, Vasostrict)
- Other vasopressors like norepinephrine, phenylephrine
- Newer formulations with alternative administration routes
What Are Current Price Points and Trends?
Current Wholesale Acquisition Cost (WAC)
| Product |
Average Price per Dose |
Notes |
| NDC 52427-0441 (Vasopressin Injection) |
$3.50 - $5.50 |
Based on recent audits; varies by supplier |
Historical Price Trends
- Prices have declined marginally over the past 5 years
- Price competition increases as patents expire and more generic manufacturers enter
- Some hospitals negotiate discounts, making actual purchase prices lower
Price Comparison with Alternatives
| Vasopressor |
Average Price per Dose |
Notes |
| Vasopressin (NDC 52427-0441) |
$3.50 - $5.50 |
Generic; multiple suppliers |
| Norepinephrine |
$1.50 - $4.00 |
Widely used; often preferred in septic shock |
| Epinephrine |
$2.00 - $4.50 |
Used in cardiac arrest and allergic reactions |
Note: These are wholesale prices; hospital procurement prices may be 10–20% lower through negotiated contracts.
What Are Price Projections for the Next 2-3 Years?
Factors Influencing Price Trajectories
- Market Competition: Increased generic entries approach saturation, likely exerting downward pressure.
- Hospital Formularies: Preference shifts may alter demand.
- Regulatory and Reimbursement Policies: Changes in Medicaid/Medicare reimbursement could influence procurement prices.
- Supply Chain Factors: Manufacturing costs and raw material availability affect pricing stability.
Projections
| Year |
Estimated Price Range |
Commentary |
| 2023 |
$3.25 - $5.00 |
Slight decline expected due to increased competition |
| 2024 |
$3.00 - $4.75 |
Continued downward pressure, stabilization expected |
| 2025 |
$2.75 - $4.50 |
Prices stabilize as market saturation is reached |
Assumptions
- No major regulatory changes or shortages
- Stable approval landscape
- Ongoing generic competition persists
What Are Strategic Considerations for Market Participants?
- Manufacturers: Focus on cost-effective production to remain competitive.
- Distributors: Optimize supply chain to leverage price stability.
- Healthcare Providers: Shift toward economic prescribing by selecting lower-cost alternatives when clinically appropriate.
- Investors: Anticipate marginal price declines but stable demand due to critical care use.
Key Takeaways
- NDC 52427-0441 (Vasopressin Injection) is a mature product with limited growth prospects.
- The U.S. hospital market constitutes most of its sales, with pricing generally between $3.25 and $5.00 per dose.
- Price trends are downward, driven by increasing generic competition and hospital formulary dynamics.
- Long-term pricing is likely to stabilize around $2.75 to $4.50 per dose by 2025.
- Market entry barriers are low, but demand remains steady due to its critical care application.
FAQs
1. Will the price of vasopressin injections increase or decrease in the future?
Prices are projected to decline gradually due to increased generic competition and hospital cost containment efforts.
2. How does vasopressin compare economically to other vasopressors?
It generally costs more than norepinephrine but remains essential in specific clinical scenarios. The choice often balances cost with clinical efficacy.
3. Are there new formulations or delivery methods in development?
Current pipelines focus on alternative routes (e.g., intranasal), but none are expected to replace injectable vasopressin in the near term.
4. How significant are supply chain disruptions for vasopressin?
While rare, they can lead to short-term price increases; long-term supply stability remains adequate.
5. What regulatory factors could influence future prices?
Patent expirations of branded alternatives and potential policy reforms on drug pricing could influence competition and cost.
Citations:
[1] Global Data, "Hospital Pharmaceuticals Market Outlook," 2023
[2] IQVIA, "U.S. Prescription Drug Market Data," 2022
[3] Department of Health and Human Services, "Critical Care Drug Utilization," 2023
